Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
04:30pm, Wednesday, 03'rd Jun 2026
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
09:00am, Wednesday, 03'rd Jun 2026
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile w
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
12:09pm, Tuesday, 02'nd Jun 2026
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
05:50pm, Monday, 01'st Jun 2026
New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NAS
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 22'nd May 2026
NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:20pm, Tuesday, 12'th May 2026
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rare disease families find roadmap to drug development at bootcamps
06:30am, Thursday, 07'th May 2026
Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
04:30pm, Wednesday, 06'th May 2026
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri
There's a New Rare-Earth Stock. Here's What Makes It Stand Out.
03:27pm, Wednesday, 06'th May 2026
Tuesday, Rare Earth Americas priced its IPO at $19 per share.
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
01:01pm, Wednesday, 06'th May 2026
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
11:01am, Wednesday, 06'th May 2026
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:00pm, Tuesday, 05'th May 2026
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Stre
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
06:11pm, Tuesday, 05'th May 2026
Ultragenyx (RARE) came out with a quarterly loss of $1.84 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $1.57 per share a year ago.
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
04:01pm, Tuesday, 05'th May 2026
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
11:01am, Wednesday, 29'th Apr 2026
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
